Navigation Links
Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
Date:11/20/2009

CARY, N.C., Nov. 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce. Cornerstone is preparing an appropriate response to the FDA.

Cornerstone has not sold any Deconsal CT products since July 2009 and has not sold any Deconsal DM products since January 2009. Net revenues from the sales of the Deconsal products in 2009 year to date are $173,498. Cornerstone does not intend to manufacture, or have manufactured, any further lots of this product.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharma
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
2. Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes
3. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
4. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
5. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
6. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
8. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
9. Reportlinker Adds Pain Therapeutics 2005: Market Dynamics and Outlook
10. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
11. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 Advanced Wound Dressings ... Advanced dressings have steadily replaced traditional bandages ... variety of wound indications, such as trauma wounds, ... control, and physical protection become increasingly critical in ... in standard therapy. This report focuses on ...
(Date:9/2/2015)... , Sept. 2, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in Boston.  The public is welcome to ... the Array BioPharma website.Event: Wells Fargo Securities Healthcare ... September 10, 2015Time:  , 10:20 a.m. Eastern Time ...
(Date:9/2/2015)... Physicians Rx Pharmacy ("PRxP") today announced that ... President and Chief Executive Officer.  Mr. Bernstein, ... Officer for Soleo Health Specialty Infusion Services, will, as ... be responsible for leading the rapidly-growing 340B pharmacy services ... Gaston on as the President and CEO of PRxP," ...
Breaking Medicine Technology:Advanced Wound Dressings - SA Analysis and Market Forecasts 2Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2
... N.M., March 11, 2011 Qforma, an advanced analytics ... Elna Hamp to Vice President, Business Development and Joann ... business models continue to evolve with the changing healthcare ... said Al Reicheg, Chief Commercial Officer of Qforma. "Our ...
... Calif., March 11, 2011 Sonitus Medical, Inc., a ... and removable hearing prosthetic to transmit sound via the ... certification for its SoundBite Hearing System. The company has ... System Approval. This is the first European regulatory certification ...
Cached Medicine Technology:Qforma Appoints Two New Executives 2Sonitus Medical Receives European CE Mark for SoundBite™ Hearing System 2
(Date:9/2/2015)... ... 2015 , ... Leah Binder, MA, MGA, president and CEO ... healthcare, will offer the keynote address at the upcoming meeting of the ACO ... Harbor, Florida, at the Innisbrook Resort and Golf Club. For an agenda and ...
(Date:9/2/2015)... (PRWEB) , ... September 03, 2015 , ... ... at Johns Hopkins University Bloomberg School of Public Health and an internationally recognized ... House Fellows program for 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate ...
(Date:9/2/2015)... Yorba Linda, CA (PRWEB) , ... September 02, 2015 , ... ... in the genome by using a complex of the Cas9 nuclease with either a ... a trans-activating RNA (tracrRNA)). The ability of any given guide RNA (sgRNA or crRNA) ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... cosponsored by the Military Officers Association of America (MOAA) and Wounded Warrior ... Military: Caring For Our Own,” expert panelists will lead interactive discussions on ...
(Date:9/2/2015)... ... September 02, 2015 , ... According to an article published August 12 by ... that aims to do away with grand juries in cases meant to decide if a ... direct response to grand jury decisions in Ferguson and New York City that absolved police ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3
... reported by researchers in the Journal of Hypertension ... morbidity and improve their atherosclerotic risk profile by ... indicated that serum lipoprotein(a), a powerful predictor of ... The researchers studied 402 patients with untreated essential ...
... new effort to re-examine very old drugs that ... that drugs worked well, has landed dozens of ... now FDA stressed that the expectorant, extended-release guaifenesin, ... to the FDA formally approving sale of Adams// ...
... Preventing and Reversing Atherosclerosis in Houston, Texas, United ... intense lifestyle changes plus pharmacologic lipid treatment reduces ... greater extent than usual-care cholesterol lowering drugs. They ... performing myocardial perfusion imaging at baseline and after ...
... An Australian study published in The New England Journal ... showed diuretics were superior to ACE (angiotensin-converting enzyme) inhibitors ... Australian study included 6,083 people who were mostly white. ... took a diuretic and those who took an ACE ...
... a study published in the British Medical Journal, older people ... The researchers from Cambridge, UK, identified a group of 2,686 ... sent either one capsule of Vitamin D3 or a placebo ... to provide them with information on bone fractures// and any ...
... knees, is a form of arthritis where one or ... in in these type of joint problems is the ... fluid that moisturizes the area. This fluid is called ... humans since 1987, after the therapy was proved beneficial ...
Cached Medicine News:
The O.R. Special Protective Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is availa...
... added an elastic belt to help lift the ... Procedure Apron features all around protection to cover ... makes wearing and removing a breeze. ,For additional ... Belts - they reduce pressure on the vertebrae ...
The O.R. Special Protective Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is availa...
The Easy Wrap Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is available in 5mm lea...
Medicine Products: